Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics
Unmodified antibodies (abs) have been successful in the treatment of hematologic malignancies, but less so for the treatment of solid tumors. They trigger anti-tumor effects through their Fc-domains, and one way to improve their efficacy is to optimize their interaction with the effectors through Fc...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2012-06-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4468/1/1/88 |